In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

CBIZ, Inc. (NYSE: CBZ), a leading national professional services advisor, announced the release of its 2025 State of ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

U.S. stock futures advance, U.S.-listed shares of Novo Nordisk fall on news its CEO is stepping down, and Charter ...